These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 31336012)
1. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. Iida S; Watanabe T; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Tobinai K Cancer Sci; 2019 Sep; 110(9):2924-2932. PubMed ID: 31336012 [TBL] [Abstract][Full Text] [Related]
2. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768 [TBL] [Abstract][Full Text] [Related]
3. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]
4. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Ailawadhi S; Sexton R; Lentzsch S; Abidi MH; Voorhees PM; Cohen AD; Rohren EM; Heitner S; Kelly K; Mackler NJ; Baer DM; Hoering A; Durie B; Orlowski RZ Clin Cancer Res; 2020 Aug; 26(15):3969-3978. PubMed ID: 32299820 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Hájek R; Masszi T; Petrucci MT; Palumbo A; Rosiñol L; Nagler A; Yong KL; Oriol A; Minarik J; Pour L; Dimopoulos MA; Maisnar V; Rossi D; Kasparu H; Van Droogenbroeck J; Yehuda DB; Hardan I; Jenner M; Calbecka M; Dávid M; de la Rubia J; Drach J; Gasztonyi Z; Górnik S; Leleu X; Munder M; Offidani M; Zojer N; Rajangam K; Chang YL; San-Miguel JF; Ludwig H Leukemia; 2017 Jan; 31(1):107-114. PubMed ID: 27416912 [TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Watanabe T; Tobinai K; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Kashihara T; Iida S Br J Haematol; 2016 Mar; 172(5):745-56. PubMed ID: 26732066 [TBL] [Abstract][Full Text] [Related]
7. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma. Sugiura I; Suzuki K; Ri M; Chou T; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Iida S Int J Hematol; 2020 Jan; 111(1):57-64. PubMed ID: 31664647 [TBL] [Abstract][Full Text] [Related]
8. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study). Abe Y; Kubonishi S; Ri M; Iino M; Sunami K; Ito T; Fukaya M; Kitano T; Ikeda S; Ota S; Kuroi T; Iriyama N; Jo T; Adachi M; Akahane D; Kai T; Kohara Y; Kadowaki N; Katayama T Future Oncol; 2024; 20(17):1191-1205. PubMed ID: 38420911 [TBL] [Abstract][Full Text] [Related]
9. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial. Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108 [TBL] [Abstract][Full Text] [Related]
10. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Chari A; Cornell RF; Gasparetto C; Karanes C; Matous JV; Niesvizky R; Lunning M; Usmani SZ; Anderson LD; Chhabra S; Girnius S; Shustik C; Stuart R; Lee Y; Salman Z; Liu E; Valent J Hematol Oncol; 2020 Aug; 38(3):353-362. PubMed ID: 32053229 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420 [TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. Berdeja JG; Gregory TK; Faber EA; Hart LL; Mace JR; Arrowsmith ER; Flinn IW; Matous JV Am J Hematol; 2021 Apr; 96(4):428-435. PubMed ID: 33421178 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484 [TBL] [Abstract][Full Text] [Related]
14. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
15. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ; Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818 [TBL] [Abstract][Full Text] [Related]
16. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). Hájek R; Bryce R; Ro S; Klencke B; Ludwig H BMC Cancer; 2012 Sep; 12():415. PubMed ID: 22992303 [TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma. Iida S; Tobinai K; Taniwaki M; Shumiya Y; Nakamura T; Chou T Int J Hematol; 2016 Nov; 104(5):596-604. PubMed ID: 27460677 [TBL] [Abstract][Full Text] [Related]
18. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538 [TBL] [Abstract][Full Text] [Related]
19. Once-weekly Bringhen S; Mina R; Petrucci MT; Gaidano G; Ballanti S; Musto P; Offidani M; Spada S; Benevolo G; Ponticelli E; Galieni P; Cavo M; Di Toritto TC; Di Raimondo F; Montefusco V; Palumbo A; Boccadoro M; Larocca A Haematologica; 2019 Aug; 104(8):1640-1647. PubMed ID: 30733270 [TBL] [Abstract][Full Text] [Related]
20. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]